Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
B-RAF is frequently mutated in solid tumors, resulting in activation of the MEK/ERK signaling pathway and ultimately tumor cell growth and survival. MEK inhibition in these cells results in cell cycle arrest and cytostasis. Here, we have shown that MEK inhibition also triggers limited apoptosis of human tumor cell lines with B-RAF mutations and that this effect was dependent on upregulation and dephosphorylation of the proapoptotic, Bcl-2 homology 3-only (BH3-only) Bcl-2 family member Bim. However, upregulation of Bim was insufficient for extensive apoptosis and was countered by overexpression of Bcl-2. To overcome apoptotic resistance, we treated the B-RAF mutant cells both with MEK inhibitors and with the BH3 mimetic ABT-737, resulting in profound synergism and extensive tumor cell death. This treatment was successful because of both efficient antagonism of the prosurvival Bcl-2 family member Mcl-1 by Bim and inhibition of Bcl-2 and Bcl-x(L) by ABT-737. Critically, addition of ABT-737 converted the predominantly cytostatic effect of MEK inhibition to a cytotoxic effect, causing long-term tumor regression in mice xenografted with human tumor cell lines. Thus, the therapeutic efficacy of MEK inhibition requires concurrent unleashing of apoptosis by a BH3 mimetic and represents a potent combination treatment for tumors harboring B-RAF mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Suppression of MEK/ERK signaling leads to the accumulation of the pro-apoptotic BCL-2 family protein BIM, which is critical for inducing apoptosis in response to an array of targeted therapies14,15.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [14]
In the citing paper
“Indeed, ERK1/2 pathway inhibitors combine with navitoclax, or the close analogue ABT-737, to induce colorectal cancer (CRC) apoptosis and tumour regression in vivo11,25,26.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [25]
In the citing paper
“Combining BRAFi or MEKi with pan-BCL2/BCL-w/BCL-XL inhibitors causes strong synergistic cell death of CRC, NSCLC and pancreatic cells and tumour regressions11,25,26.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [25]
In the citing paper
“This is also true in other tumour lineages, such as CRC; however, whereas increased BIM and BMF primed CRC cells to undergo substantial apoptosis following treatment with the BCL2/BCL-w/BCL-XL inhibitor navitoclax/ABT-26311,25,26, this combination was notably less effective in melanoma11,27,28.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [25]
In the citing paper
“An increase in the formation of MCL1:BIM complexes has been documented after exposure of BRAF-mutant melanoma cells to the BCL2/BCL-XL inhibitor ABT-737 (20) and in KRAS-mutant cells of different origin treated with navitoclax (18, 21).”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [20]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Strasser, A., O'Connor, L., & Dixit, V. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.217 · Cited by 1,351
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
Bim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166
Self-citation
Research works printed but not linked: 3
- Cohen, 2002, Clin. Cancer Res., 8, 3728
- Brose, 2002, Cancer Res., 62, 6997
- Bos, 1989, Cancer Res., 49, 4682
Cited by
Items 101–200 of 206
Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
Wei, W., Sun, Z., Shen, C., Song, H.-J., Zhang, X., Qiu, Z., & Luo, Q. (2017) · Theranostics · doi:10.7150/thno.17322 · Cited by 40
Grazia, G., Penna, I., Perotti, V., Anichini, A., & Tassi, E. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2491 · Cited by 40
Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells
Katz, S. G., LaBelle, J. L., Meng, H., Valeriano, R. P., Fisher, J. K., Sun, H. H., Rodig, S. J., Kleinstein, S. H., & Walensky, L. D. (2013) · Blood · doi:10.1182/blood-2013-04-499079 · Cited by 42
Cell death pathology: The war against cancer
Rufini, A., & Melino, G. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.09.110 · Cited by 44
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
Ramakrishnan, V. G., Miller, K. C., Macon, E. P., Kimlinger, T. K., Haug, J. L., Kumar, S., Gonsalves, W. I., Rajkumar, S. V., & Kumar, S. K. (2019) · Haematologica · doi:10.3324/haematol.2018.211110 · Cited by 37
Passante, E., Würstle, M. L., Hellwig, C. T., Leverkus, M., & Rehm, M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.106 · Cited by 36
Knickelbein, K., Tong, J., Chen, D., Wang, Y.-J., Misale, S., Bardelli, A., Yu, J., & Zhang, L. (2018) · Oncogene · doi:10.1038/s41388-018-0289-x · Cited by 33
Bcl-2 family inhibitors sensitize human cancer models to therapy
Valentini, E., Martile, M. D., Brignone, M., Caprio, M. D., Manni, I., Chiappa, M., Sergio, I., Chiacchiarini, M., Bazzichetto, C., Conciatori, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05963-1 · Cited by 38
Naik, E., O'Reilly, L. A., Asselin-Labat, M.-L., Merino, D., Lin, A., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100951 · Cited by 31
“Pertinently, small molecule mimetics of BH3-only proteins, such as ABT-737, have shown efficacy in preclinical solid tumor models (Oltersdorf et al., 2005; Cragg et al., 2007, 2008).”
BackgroundSelf-citationChoi, E., Oh, S., Jang, B., Yu, H., Shin, J., Cho, N., Yang, I., Won, D., Kwon, H.-J., Hong, S., et al. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0318-8 · Cited by 31
Nishihara, S., Yamaoka, T., Ishikawa, F., Higuchi, K., Hasebe, Y., Manabe, R., Kishino, Y., Kusumoto, S., Andō, K., Kuroda, Y., et al. (2022) · Genes · doi:10.3390/genes13122183 · Cited by 40
Conrad, M., Strasser, A., Jost, P. J., Yuan, J., Shao, F., Vandenabeele, P., & Wahida, A. (2026) · Cell · doi:10.1016/j.cell.2026.03.024 · Cited by 46
Self-citationCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
McArthur, G. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00161 · Cited by 34
Melanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 34
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Harada, H., & Grant, S. (2012) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i2.40 · Cited by 34
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
Song, J., Kim, C., Je-Hwan, L., Jang, S. J., Lee, S.-W., Hwang, J. J., Lim, C., Lee, G., Seo, J., Cho, S. Y., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0030-0 · Cited by 31
Transcriptional Regulation in Melanoma
Mitra, D., & Fisher, D. E. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.003 · Cited by 36
Reynoso, D., Nolden, L. K., Yang, D., Dumont, S., Conley, A. P., Dumont, A. G., Zhou, K., Duensing, A. U., & Trent, J. C. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.10.003 · Cited by 35
Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 32
Keuling, A. M., Andrew, S. E., & Tron, V. A. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00698.x · Cited by 32
Sakuma, Y., Takeuchi, T., Nakamura, Y., Yoshihara, M., Matsukuma, S., Nakayama, H., Ohgane, N., Yokose, T., Kameda, Y., Tsuchiya, E., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2676 · Cited by 28
Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib
Wei, W., Shen, C., Song, H.-J., Qiu, Z., & Luo, Q. (2016) · Oncology Reports · doi:10.3892/or.2016.4918 · Cited by 31
Rohrbeck, L., Gong, J., Lee, E. F., Kueh, A. J., Behren, A., Tai, L., Lessène, G., Huang, D. C. S., Fairlie, W. D., Strasser, A., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.96 · Cited by 29
Self-citationTargeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 28
Measurement of BH3-only protein tolerance
Dai, H., Ding, H., Peterson, K. L., Meng, X. W., Schneider, P. A., Knorr, K. L. B., & Kaufmann, S. H. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.156 · Cited by 29
Ku, B. M., Jho, E. H., Bae, Y.-H., Sun, J., Ahn, J. S., Park, K., & Ahn, M. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0163-9 · Cited by 26
Fournier, F., Diaz-Marin, R., Pilon, F., Neault, M., Juneau, R., Girouard, G., Wilson, A. M., Larrivée, B., Mallette, F. A., Crespo‐Garcia, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209973120 · Cited by 26
Sale, M. J., & Cook, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12220 · Cited by 20
Stamelos, V. A., Redman, C. W. E., & Richardson, A. (2012) · Journal of Molecular Signaling · doi:10.1186/1750-2187-7-12 · Cited by 30
Novel Targets for the Treatment of Melanoma
Ambrosi, L., Khan, S. A., Carvajal, R. D., & Yang, J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0849-4 · Cited by 24
Quezada, M. J., Picco, M. E., Villanueva, M. B., Castro, M. V., Barbero, G., Fernández, N., Illescas, E., & Lopez‐Bergami, P. (2020) · Cancers · doi:10.3390/cancers13010078 · Cited by 26
Anticancer therapy: boosting the bang of Bim
Hendrickson, A. W., Meng, X. W., & Kaufmann, S. H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37553 · Cited by 23
BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells
Hartman, M. L., Gajos-Michniewicz, A., Talaj, J. A., Mielczarek-Lewandowska, A., & Czyż, M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.036 · Cited by 22
Hebron, K. E., Wan, X., Roth, J. S., Liewehr, D. J., Sealover, N. E., Frye, W. J. E., Kim, A., Stauffer, S., Perkins, O. L., Sun, W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1646 · Cited by 25
BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling
Polzien, L., Baljuls, A., Albrecht, M., Hekman, M., & Rapp, U. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177345 · Cited by 20
Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review
Liang, X.-W., Liu, B., Chen, J.-C., Cao, Z. W., Chu, F.-R., Xiong, L., Wang, S.-Z., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1177466 · Cited by 20
Eder, S., Lamkowski, A., Priller, M., Port, M., & Steinestel, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3935 · Cited by 21
Grabow, S., Waring, P., Happo, L., Cook, M., Mason, K. D., Kelly, P. N., & Strasser, A. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.133 · Cited by 20
Self-citationSullivan, R. J., & Atkins, M. B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504709 · Cited by 21
Becker, J. H., Metropulos, A. E., Spaulding, C., Marinelarena, A. M., Shields, M. A., Principe, D. R., Pham, T. D., & Munshi, H. G. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3574 · Cited by 17
Molecular-targeted therapy in malignant melanoma
Sullivan, R. J., & Atkins, M. B. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.20 · Cited by 16
Drug Targeting of Oncogenic Pathways in Melanoma
Fecher, L. A., Amaravadi, R. K., Schuchter, L. M., & Flaherty, K. T. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.004 · Cited by 14
CAML regulates Bim-dependent thymocyte death
Edgar, C. E., Lindquist, L. D., McKean, D. L., Strasser, A., & Bram, R. J. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.30 · Cited by 13
Self-citationEleveld, T. F., Vernooij, L., Schild, L. G., Koopmans, B., Alles, L. K., Ebus, M. E., Dandis, R., van Tinteren, H., Caron, H. N., Köster, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2023.1130034 · Cited by 16
Ezzoukhry, Z., Louandre, C., François, C., Saidak, Z., Godin, C., Mazière, J., & Galmiche, A. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070565 · Cited by 15
Shen, Y., Ren, X., Ding, K., Zhang, Z., Wang, D., & Pan, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2090 · Cited by 11
Rice, S. J., Liu, X., Wang, H., & Belani, C. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217657 · Cited by 11
Shin, J., Kim, L., Lee, S.-J., Jeong, J. H., Jung, J., Lee, H. N., Hong, I., & Cho, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5523 · Cited by 11
BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage
Brinkmann, K., Waring, P., Glaser, S. P., Wimmer, V. C., Cottle, D. L., Tham, M. S., Nhu, D., Whitehead, L. W., Delbridge, A. R. D., Lessène, G., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020105561 · Cited by 10
Self-citationLKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“Suppression of MEK/ERK signaling leads to the accumulation of the pro-apoptotic BCL-2 family protein BIM, which is critical for inducing apoptosis in response to an array of targeted therapies 14,15 .”
Manzano-Muñoz, A., Alcon, C., Menéndez, P. R., Ramírez, M. R., Seyfried, F., Debatin, K., Meyer, L. H., Samitier, J., & Montero, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.695225 · Cited by 10
Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
He, H., Xu, C., Cheng, Z., Qian, X., & Zheng, L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902150555 · Cited by 11
Lin, C., Shen, C., Lee, J., Huang, C., Yang, C.-H., Kuo, W., Chang, D., Hsiung, C., Kuo, K., Chen, T. W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124908 · Cited by 10
Embracing synthetic lethality of novel anticancer therapies
Kamal, Ä., Shaik, T. B., & Malik, M. S. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1072167 · Cited by 10
Guan, Y., Tu, K., Huang, Q., & Liu, F. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.103 · Cited by 9
Happo, L., Strasser, A., & Scott, C. L. (2009) · Wiley eBooks · doi:10.1002/9780470015902.a0021569 · Cited by 9
Self-citationAntiangiogenic and antiapoptotic treatment in advanced melanoma
Nikolaou, V. A., Stratigos, A., Bafaloukos, D. I., & Katsambas, A. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.018 · Cited by 8
SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors
Kiga, M., Nakayama, A., Shikata, Y., Sasazawa, Y., Murakami, R., Nakanishi, T., Tashiro, E., & Imoto, M. (2015) · Scientific Reports · doi:10.1038/srep08155 · Cited by 9
Yu, M., Nah, G. S. S., Krishnan, V., Sulaimi, F. N., Ng, K. P., Wang, C., Bhatt, S., Chuah, C. T. H., Bergstrom, D. E., & Ong, S. T. (2024) · Leukemia · doi:10.1038/s41375-024-02418-0 · Cited by 9
Principe, D. R., Becker, J. H., Metropulos, A. E., Marinelarena, A. M., Pham, T. D., Aissa, A. F., & Munshi, H. G. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0483 · Cited by 10
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy
Vari, S., Pilotto, S., Maugeri‐Saccà, M., Ciuffreda, L., Incani, U. C., Falcone, I., Curatolo, A. D., Ceribelli, A., Gelibter, A. J., Maria, R. D., et al. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.843523 · Cited by 6
Sahoo, S., Suvarna, S., Chandra, A., Wahi, S., Kumar, P., & Khanna, G. (2013) · PubMed · Cited by 9
The Potential Benefits of BIM in the Further Pursuit of Biomarker Discovery in Cancer Therapeutics
Yoshida, T., & Haura, E. B. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0193 · Cited by 6
SPZ1 promotes deregulation of Bim to boost apoptosis resistance in colorectal cancer
Liu, X., Zheng, C., Wang, T., Xu, J. Y., Zhang, M., Gou, L., Jin, L., Qi, X., Zeng, X., Li, H., et al. (2020) · Clinical Science · doi:10.1042/cs20190865 · Cited by 5
Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells
Tchelougou, D., Malaquin, N., Cardin, G. B., Desmul, J., Turcotte, S., & Rodier, F. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1368711 · Cited by 6
Sale, M. J., & Cook, S. J. (2014) · Biochemical Journal · doi:10.1042/bj20131346 · Cited by 6
Improving apoptotic responses to targeted therapy
Haq, R., & Fisher, D. E. (2013) · Oncotarget · doi:10.18632/oncotarget.1261 · Cited by 4
Waldron, N. R., Silva, D. D., Westaby, D., Jiménez‐Vacas, J. M., Taylor, J., & Sharp, A. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03441-x · Cited by 5
Régulation de la survie cellulaire par les kinases de la famille RAF
Galmiche, A., & Ezzoukhry, Z. (2010) · médecine/sciences · doi:10.1051/medsci/2010268-9729 · Cited by 4
Damnjanović, I. (2019) · FARMACIA · doi:10.31925/farmacia.2019.2.5 · Cited by 3
Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice
Bosma, N. A., Singla, A. K., Downey, C. M., & Jirik, F. R. (2014) · Oncoscience · doi:10.18632/oncoscience.102 · Cited by 3
Bim regulation miRrors microRNA 17∼92 cluster expression in endothelial cells in vivo
Meng, X. W., & Kaufmann, S. H. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.127 · Cited by 3
Pignataro, C., Zoppoli, P., Cappelli, L. V., Yoffe, L., Moretti, M., Izzo, M., Mallia, S., Kayembe, C., Taylor, A., Petrillo, G., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015322 · Cited by 2
Rational Strategies for Combining Bcl-2 Inhibition with Targeted Drugs for Anti-Tumor Synergy
Schwab, E., Chen, J. B., Huynh, J., Ji, J., Arora, M., Cho, M. T., & Kim, E. J.-H. (2019) · Journal of Cancer Treatment and Diagnosis · doi:10.29245/2578-2967/2019/4.1172 · Cited by 2
The future of targeted therapy approaches in melanoma
Cantini, L. P., Meier, F. E., Sondak, V. K., & Smalley, K. S. M. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440902828298 · Cited by 2
Eleveld, T. F., Vernooij, L., Schild, L. G., Koopmans, B., Alles, L. K., Ebus, M. E., Sluis, P. V., Caron, H. N., Köster, J., Versteeg, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.12.945089 · Cited by 2
Berry, S. M., Carlin, B. P., Lee, J. J., & Muller, P. (2010) · CRC Press eBooks · doi:10.1201/ebk1439825488-6 · Cited by 1
Targeting apoptosis is the major battle field for killing cancers
Liu, X. (2015) · World Journal of Translational Medicine · doi:10.5528/wjtm.v4.i3.69 · Cited by 1
Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments
Venerando, A., Lovison, D., & Marco, R. D. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00074 · Cited by 1
Targeted siRNA Delivery Methods for RNAi-Based Therapies
Chen, D. (2013) · Scholarship@Western (Western University) · Cited by 3
Molecular-Targeted Therapy for Melanoma
RUSSO, A. E., Bevelacqua, Y., Marconi, A., Veronesi, A., & Libra, M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_20 · Cited by 1
Reynoso, D. (2012) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Tuzlak, S., & Villunger, A. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0021569.pub2 · Cited by 1
Konopleva, M. Y., Milella, M., Ruvolo, P. P., Watts, J. C., Ricciardi, M. R., Korchin, B., Teresa, M., Bornmann, W. G., Tsao, T., Bergamo, P., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02339-y · Cited by 1
BH3-Only Proteins in Cancer and Apoptosis
Ghiotto, F., Tenca, C., Fais, F., & Bruno, S. (2013) · Springer eBooks · doi:10.1007/978-94-007-6211-4_9
TGFβ and Bim: Partners in cell death
Wildey, G. M., & Howe, P. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/44880
Quoi de neuf en recherche dermatologique ?
Dereure, O. (2009) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(09)73382-4
chemoresistance in Burkitt lymphoma Reversion of epigenetically mediated BIM silencing overcomes
Calasanz, M. J., Panizo, C., Richter, J. Á., Hernández‐Rivas, J. M., Richter-Larrea, A., Robles, E. F., Fresquet, V., Beltrán, E., & Rullan, A. (2014)
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. F. L., & Wellbrock, C. (2013) · University of Huddersfield Repository (University of Huddersfield)
Leading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members
Yazbeck, V. Y., & Johnson, D. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_9
Bosma, N. A. (2013) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27979
Control of Cell Survival and Apoptosis
Gray, D. H. D., & Strasser, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.11009-4
Self-citationLeal, C. T. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2018.tde-06042018-114114
Keuling, A. M. (2010) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3cq5d
Large-Scale Analysis of Cell Death Phenotypic HeterogeneityPreprint
Inde, Z., Forcina, G. C., Denton, K., & Dixon, S. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.28.970079
Brinkmann, K., Waring, P., Glaser, S. P., Wimmer, V. C., Nhu, D., Whitehead, L. W., Delbridge, A. R. D., Lessène, G., Herold, M. J., Kelly, G. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.28.055665
Self-citationBAD Phosphorylation: A Novel Link between Apoptosis and Cancer
Polzien, L. (2011)
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1
Pikman, Y., Tasian, S. K., Sulis, M. L., Stevenson, K. E., Blonquist, T. M., Winger, B. A., Cooper, T. M., Pauly, M. G., Maloney, K. W., Burke, M. J., et al. (2023) · doi:10.1158/2159-8290.c.6549352
Metadata
- Authors
- Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L.
- Affiliations
- Walter and Eliza Hall Institute of Medical Research (AU)
- University of Southampton (GB)
- Corresponding author
- Strasser, Andreas
- Venue
- Journal of Clinical Investigation
- Published
- 2008-11-03
- Volume
- 118
- Issue
- 11
- Pages
- 3651-3659
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2571034
- OpenAlex
- W2167334545
- Cited by
- 207
- References
- 36
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 12 · 2019: 10 · 2018: 5 · 2017: 8 · 2016: 13 · 2015: 18 · 2014: 15 · 2013: 17 · 2012: 19
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Institutes of Health (CA 43540)
- Medical Research Council
- National Health and Medical Research Council (257502)
- National Cancer Institute (#CA 80188, R01CA043540, CA 43540, R01CA080188)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- BRAF mutation, MEK inhibitors, BH3 mimetics, ABT-737, building information modeling, Bcl-2, Mcl-1, Bcl-xL, apoptosis, MEK/ERK signaling, combination therapy, tumor regression, cytostasis, Bcl-2 family proteins
- MeSH terms
- Bcl-2-Like Protein 11, Biphenyl Compounds, Humans, Membrane Proteins, Mutation, Neoplasms, Nitrophenols, Piperazines, Proto-Oncogene Proteins, Sulfonamides, Molecular Mimicry, HT29 Cells, Proto-Oncogene Proteins c-bcl-2, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Apoptosis Regulatory Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.